ArticleNature communications2023

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.

Esther R Berko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.